SOLARA ACTIVE PHARMA SCIENCES LIMITED — Board/Management Information 2022

Feb 9, 2022

Communication Address : Solara Active Pharma Sciences Limited Batra Centre No. 28. Sardar Patel Road. Post Box 2630 Guindy, Chennai- 600 032, India Tel : +91 44 43446700. 22207500 Fax : +91 44 22350278 E-n1ail : info@sola1a.con1 www.solara.co in

February 9, 2022

The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001

Scrip Code: 541540

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai- 400 051

Scrip Code: SOLARA

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)- Change in Key Managerial Personnel of the Company

Pursuant to Regulation 30 read with Part A, Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), we wish to inform you that the Board of Directors of the Company has taken on record/approved the following changes in the Key Managerial Personnel (KMP) at its meeting held on February 9, 2022.

Name of the Director	Resignation I AJ!f!_Ointment
Mr. Bharath R Sesha	Resigned as a Managing Director & Chief Executive Officer
(DIN: 01983066)	(MD & CEO) and Director of the Company.
Mr. Rajender Juvvadi Rao(DIN: 00083540)	Appointed as Managing Director & Chief Executive Officer(MD & CEO) of the Company. The appointment is subject tothe approval of shareholders of the Company, which shall besought separately.
	Mr. Rajender Rao is currently the Executive Vice Chairman of
	the Company has been given the responsibility of MD & CEO.

Mr. Rajender Juvvadi Rao is not debarred from holding office of director by virtue of any order by the Securities and Exchange Board of India ("SEBI") or any other such authority.

The Board also approved the resignation of Mr. Rajesh Salwan as Chief Operating Officer of the Company.

The Board has requested the Mr. Rajender Juvvadi Rao to discuss with Mr. Bharath and finalize the transition plan. The date of changes will be intimated to the Stock Exchanges, once completion of the transition plan.

Communication Address: Solara Active Pharma Sciences Limited Batra Centre No. 28, Sardar Patel Road, Post Box 2630 Guindy. Chennai - 600 032. India Tel : +91 44 43446700. 22207500 Fax : +91 44 22350278 !::-mall : 1nto@solara.com wwvV.solara.co.in

Please note that the relevant details regarding the change in directors required to be disclosed under the SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015, are enclosed herewith in the annexure to this letter. We request you to take the same on record.

Thanking you, Yours faithfully, ~~lct~arma Sciences Limited 1 Murali Krishna Company Secretary

End: As above.

ANNEXURE

Name of Director	Mr. Bharath R Sesha (DIN: 01983066)
Reason for change, viz,resignation	Mr. Bharath has tendered his resignation as ManagingDirector & CEO and Director of the Company to pursueinterests outside Solara.
Date of cessation	The resignation is effective from the completion of transitionplan.
Brief profile	Not Applicable
Disclosure of relationshipbetween directors	Not Applicable

Name of Key Managerial	Mr. Rajesh Salwan
Personnel
Reason for change, viz,	Mr. Rajesh Salwan has tendered his resignation as Chief
resignation	Operating Officer of the Company to pursue interests
	outside Solara.
Date of cessation	The resignation is effective from 31st March 2022.
Brief profile	Not Applicable
Disclosure of relationship	Not Applicable
between directors

Communication Address: Solara Active Pharma Sciences Limited Batra Centre No. 28. Sardar Patel Road. Post Box 2630 Guindy, Chennai - 600 032, India Tel : +91 44 43446700. 22207500 Fax : +91 44 22350278 1:.-mail : lnto(Qlsolara.com vvww.solara.co.in

Name of Director	Mr. Rajender Juvvadi Rao (DIN: 00083540)
Reason for change, viz,appointment	Consequent to the resignation of Mr. Bharath R Sesha asManaging Director and CEO of the Company, the Board ofDirectors of the Company, pursuant to the recommendationby the Nomination and Remuneration Committee, approvedthe appointment of Mr. Rajender Rao as Managing Director& Chief Executive Officer (MD & CEO) of the Company fromthe date of completion of transition plan, subject to theapproval of the shareholders of the Company.Presently Mr. Rajender Rao is Executive Vice Chairman of theCompany has been given the expanded responsibility anddesignated as MD & CEO, who succeeds Mr. Bharath.
Date of appointment	The appointment is effective from the date of completion oftransition plan.
Term of Appointment	Appointed for a period of 3 (three) years from the date ofappointment
Brief profile	Academic Qualifications:Mechanical Engineering from Osmania University 1988.PGDIT from Indian Institute of Foreign Trade (liFT) New Delhi1992.Commenced Professional career with Reliance Industries Ltdhandling exports of Liquids.1996-1998NicholasPiramalLtd: JoinedthefirstasEmployee for Nicholas Piramal. Started Pharma tradingbusiness and later co-founded "RA Chempharma" in 2003and acquired a loss making company. Transformed the lossmaking acquisition into a viable profit making unit within aspan of two years. Envisioned an integrated vertical modelas the essence of success and value creation in pharma -aofmovethatinitiatedaseriesacquisitionsandamalgamations. This resulted in creation of an API, FDF anda Bio analytical and bio equivalence study facility completingthe vertical integration. Focus on organic growth thereafterled to business consolidation and building of teams ofintegrity, competencies and abilities. The three divisions puttogetherhadaround1000employees.Theproduct
	identification andselection, developing niche productsunder API and FDF and bringing in vertical integration into

Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636

Communication Address : Sciara Active Pharma Sciences Limited Batra Centre No. 28. Sardar Patel Road. Post Box 2630 Guindy, Chennai - 600 032. India Tel : +91 44 43446700. 22207500 Fax : '91 44 22350278 E-mail : info@solara.com vV\NW.solara.co.in

	-certain products have been the key strengths that Raj hasbrought to fore in driving Ra Chern into the entity that it hadevolved into. Ra Chern faced multiple regulatory audits fromUSFDA, UK MHRA, European authorities across all the threedivisions and the teams had reached a state of preparednessthat enables practicing highest standards of manufacturingand record keeping that enables Audit readiness on anongoing basis. A widely dispersed shareholding led to adecision to sell majority stake in "ra chem" to Microlabs,Bengaluru towards end of 2016 that enabled him to ventureinto and create a new entity Aurore Life Sciences Pvt Ltd-apure play API Player.
	Within Four years of its journey, Aurore hasreachedRevenues of about INR 550 crores with a healthy bottom lineand has created manufacturing capacities of 800 KL. Auroreis poised for an aggressive growth with the backing of a verycompetitive team including a strong R&D team_
	He is also a Director on the Board of the followingCompanies: -•Aurore Life Sciences Private Limited•Aurore Pharmaceuticals Private Limited•R. A. Labels and Stickers Private Limited
Disclosure of relationship	Mr. Rajender Rao is not related to any Director of the
between directors	Company.